Altre lingue NP Inc.

Azioni

A291230

KR7291230001

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
2.645 ^KRW	-2,04%		-2,76%	-18,62%

27/03	Algernon Pharmaceuticals afferma che l'acquisizione del programma Ifenprodil è stata completata dall'azienda statunitense	MT
07/03	In calo del 17%, BioVaxys Technology Corp. fornisce un aggiornamento bisettimanale sullo stato di MCTO	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Ultra Lithium Provides Bi-Weekly Default Status Report	03/04
Shanaya’s Subsidiary Enters MOU with Ngee Ann Polytechnic; Shares Surge 10%	29/03
Algernon Pharmaceuticals Says Acquisition of Ifenprodil Program Completed by US Company	27/03
Down 17%, BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update	07/03
MCF Energy Acquired "Accretive" Czech Gas Projects With "Immediate Production And Growth Potential"	26/02
MCF Energy Acquires Accretive Czech Gas Projects with Immediate Production and Growth Potential	26/02
Vizsla Silver Up 0.75% In US Premarket After Reporting Additional High Grade Intercepts at La Luisa	13/02
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast	30/11
Algernon Pharma in LOI For Acquisition of its Chronic Cough Research Program For US$2 Million and 20% Equity Stake	22/11
ETF de la semana: Un pie en la renovación de las infraestructuras estadounidenses	03/11
ETF de la semana: Puede que el gas no haya dicho su última palabra	19/10/23
ETF de la semana: Diversificar con bonos	11/10/23
Aehr Test Systems Receives Initial Order From Unnamed New Customer for Wafer Level Test, Burn-in Systems	18/09/23
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH	06/09/23
Novelplus Technology Trims Loss in H1	15/08/23
Napo Pharmaceuticals Submits Funding Application to BARDA for NP-300 Development	09/08/23
Moody's Withdraws Ratings on Austria's Addiko Bank	09/08/23
Algernon Pharmaceuticals Engage Maxim Group to Explore Spin-Off of Ifenprodil Phase 2 Chronic Cough Drug Development Program	27/06/23
Algernon Pharmaceuticals Receives Notice of Allowance From Japanese Patent Office for Repirinast and Treatment of CKD	31/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NP Inc.

Azioni

A291230

KR7291230001

Altre lingue

Filtri